Products Categories
CAS No.: | 56390-09-1 |
---|---|
Name: | Epirubicin hydrochloride |
Molecular Structure: | |
Formula: | C27H29NO11.HCl |
Molecular Weight: | 579.99 |
Synonyms: | 5,12-Naphthacenedione,10-[(3-amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,hydrochloride, (8S,10S)- (9CI);5,12-Naphthacenedione,10-[(3-amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,hydrochloride, (8S-cis)-;4'-Epidoxorubicin hydrochloride;4'-epi-Adriamycinhydrochloride;Ellence;Epidoxorubicin hydrochloride; |
EINECS: | 260-145-2 |
Density: | 1.61 g/cm3 |
Melting Point: | 185 °C dec |
Boiling Point: | 810.3 °C at 760 mmHg |
Flash Point: | 443.8 °C |
Appearance: | Orange-red crystalline solid |
Hazard Symbols: | Xn |
Risk Codes: | 22-63-62-46-40 |
Safety: | 36/37/38-45-46 |
PSA: | 206.07000 |
LogP: | 1.50360 |
What can I do for you?
Get Best Price
IUPAC Name: (7S,9S)-7-[(2R,4S,5R,6S)-4-Amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione hydrochloride
Synonyms of Epirubicin hydrochloride (CAS NO.56390-09-1): (1S,3S)-3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside hydrochloride ; 4'-Epidoxorubicin hydrochloride ; 4'-Epi-Adriamycin hydrochloride ; Epidoxorubicin hydrochloride ; Farmorubicin ; Pharmorubicin
CAS NO: 56390-09-1
Molecular Formula: C27H29NO11.HCl
Molecular Weight: 579.99
Molecular Structure:
EINECS: 260-145-2
Flash Point: 443.8 °C
Enthalpy of Vaporization: 123.51 kJ/mol
Boiling Point: 810.3 °C at 760 mmHg
Vapour Pressure: 9.64E-28 mmHg at 25°C
Melting Point: 185°C dec
Appearance: Orange-Red Crystalline Solid
Product Categories of Epirubicin hydrochloride (CAS NO.56390-09-1): Antibiotics;Intermediates & Fine Chemicals;Pharmaceuticals
Epirubicin hydrochloride (CAS NO.56390-09-1) is used as an antineoplastic mainly used for treatment of acute and chronic leukemia, malignant lymphoma.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LD50 | intravenous | 2250ug/kg (2.25mg/kg) | Drugs in Japan Vol. -, Pg. 200, 1990. | |
mouse | LD50 | intravenous | 31500ug/kg (31.5mg/kg) | Drugs in Japan Vol. -, Pg. 200, 1990. | |
mouse | LD50 | oral | > 2gm/kg (2000mg/kg) | Drugs in Japan Vol. -, Pg. 200, 1990. | |
mouse | LD50 | subcutaneous | 37500ug/kg (37.5mg/kg) | Drugs in Japan Vol. -, Pg. 200, 1990. | |
rat | LD50 | intraperitoneal | 10800ug/kg (10.8mg/kg) | Drugs in Japan Vol. -, Pg. 200, 1990. | |
rat | LD50 | intravenous | 17mg/kg (17mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 740, 1995. | |
rat | LD50 | oral | 1350mg/kg (1350mg/kg) | Drugs in Japan Vol. -, Pg. 200, 1990. | |
rat | LD50 | subcutaneous | 17600ug/kg (17.6mg/kg) | Drugs in Japan Vol. -, Pg. 200, 1990. | |
women | TDLo | intravenous | 1622mg/kg (1622mg/kg) | SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS | Lancet. Vol. 2, Pg. 629, 1986. |